

**Remarks/Arguments**


Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments. A new  
5 abstract has been added.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to Deposit  
10 Account No. 260166 referencing Attorney Docket No. 101219-1P US.

Respectfully submitted,

15



Name: Karen H. Kondrad  
Dated: April 7, 2006  
Reg. No.: 38,212  
Phone No.: (302) 886-8975

20

Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
25 DE-19850-5437